Sasikala Mitnala

Dr. Sasikala Mitnala

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2022 in Science Immunology
Verified
Journal Article
Open access
RKRajendra Karki
Rajendra Karki
SLSangJoon Lee
SangJoon Lee
Raghvendra MallRaghvendra Mall
Raghvendra Mall
NPNagakannan Pandian
Nagakannan Pandian
YWYaqiu Wang
Yaqiu Wang
Thirumala-Devi KannegantiThirumala-Devi Kanneganti
Thirumala-Devi Kanneganti
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), continues to cause substantial morbidity and mortality in the ongoing global pandemic. Understanding the fundamental mechanisms that govern innate immune and inflammatory responses during SARS-CoV-2 infection is critical for developing effective therapeutic strategies. Whereas interferon (IFN)–based therapies are generally expected to be beneficial during viral infection, clinical trials in COVID-19 have shown limited efficacy and potential detrimental effects of IFN treatment during SARS-CoV-2 infection. However, the underlying mechanisms responsible for this failure remain unknown. In this study, we found that IFN induced Z-DNA-binding protein 1 (ZBP1)–mediated inflammatory cell death, PANoptosis, in human and murine macrophages and in the lungs of mice infected with β-coronaviruses, including SARS-CoV-2 and mouse hepatitis virus (MHV). In patients with COVID-19, expression of the innate immune sensorZBP1was increased in immune cells from those who succumbed to the disease compared with those who recovered, further suggesting a link between ZBP1 and pathology. In mice, IFN-β treatment after β-coronavirus infection increased lethality, and genetic deletion ofZbp1or its Zα domain suppressed cell death and protected the mice from IFN-mediated lethality during β-coronavirus infection. Overall, our results identify that ZBP1 induced during coronavirus infection limits the efficacy of IFN therapy by driving inflammatory cell death and lethality. Therefore, inhibiting ZBP1 activity may improve the efficacy of IFN therapy, paving the way for the development of new and critically needed therapeutics for COVID-19 as well as other infections and inflammatory conditions where IFN-mediated cell death and pathology occur.

1 July 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SMSasikala Mitnala
Sasikala Mitnala
JSJaggaiahgari Shashidhar
Jaggaiahgari Shashidhar
GDGujjarlapudi Deepika
Gujjarlapudi Deepika
VRVishnubhotla Ravikanth
Vishnubhotla Ravikanth
VKVemula Venkata Krishna
Vemula Venkata Krishna
DRDuvvur Nageshwar Reddy
Duvvur Nageshwar Reddy
The efficacy of COVID-19 vaccines to generate immunological memory post-vaccination has not previously been studied. To assess immunological memory in previously SARS-CoV-2 infected individuals after a single dose of mRNA vaccine. Healthcare workers (n = 280) were enrolled after obtaining written informed consent and grouped under previously infected and no prior exposure (reverse transcription-polymerase chain reaction positive and negative, respectively). Blood was drawn at baseline and post-vaccination (single dose of COVISHIELD) for enumerating neutralizing antibodies by chemiluminescence and memory T- and B-cells by flow cytometry. Post vaccination, compared with the no prior exposure group, the previously infected group had higher levels of: antibody response (1124.73 ± 869.13 vs 94.23 ± 140.06 AU/ml, p = 0.0001); CD4 memory T-cells: central memory CCR7+CD45RA- (p = 0.0001), effector memory CCR7-/CD45RA- (p = 0.01); total CD8+ T-cells (p = 0.004); CD8+ naïve T-cells CCR7+CD45RA+ (p = 0.01); and memory B-cells CD20+CD27+ (p = 0.0001). Single-dose vaccination elicited higher neutralizing antibody response and protective immunity in individuals who had recovered from SARS-CoV-2 infection compared with those with no prior exposure.

21 July 2021 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
PDF file
RVRavikanth Vishnubhotla
Ravikanth Vishnubhotla
SMSasikala Mitnala
Sasikala Mitnala
VKVijayasarathy Ketavarapu
Vijayasarathy Ketavarapu
NDNageshwar Reddy Duvvur
Nageshwar Reddy Duvvur
Introduction: Human leukocyte antigen (HLA) variability has been demonstrated to be associated with susceptibility/severity of COVID‐19. High‐resolution HLA genotyping to identify alleles associated with severe COVID‐19 in an Indian cohort was performed.Methods: Quantitative reverse‐transcription polymerase chain reaction‐confirmed SARS‐CoV‐2‐positive patients with mild/moderate/severe disease (n = 54) and asymptomatic (n = 42) were recruited and genotyped for 11‐HLA loci on MiSeq using NGSgo®‐MX11‐3 and analyzed (NGSengine; GenDx).Results: A significant difference in alleles between the groups was identified for HLA‐C*04:01:01:01, HLA‐DRB5*01:01:01:02, HLA‐DQA1*03:01:01:01, HLA‐DPB1*04:01:01:41, and HLA‐DPA1*01:03:01:02. Alleles namely, HLA‐C*04:01:01:01 (OR: 5.71; 95% CI: 1.2–27.14; p = .02), HLA‐DRB5*01:01:01:02 (OR: 2.94; 95% CI: 1.1–7.84; p = .03), DQA1*03:01:01:01 (OR: 22.47; 95% CI: 1.28–393.5; p = .03), HLA‐DPB1*04:01:01:41 (OR: 9.44; 95% CI: 0.5–175.81; p = .13), and HLA‐DPA1*01:03:01:02 (OR: 8.27; 95% CI: 2.26–30.21; p = .001) were associated with severe COVID‐19.Conclusion: Genotyping for these alleles will enable identification of individuals at risk of severe disease and stratification for preferential vaccination.

14 December 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
SJShashidhar Jaggaiahgari
Shashidhar Jaggaiahgari
AMApoorva Munigela
Apoorva Munigela
SMSasikala Mitnala
Sasikala Mitnala
DGDeepika Gujjarlapudi
Deepika Gujjarlapudi
VSVenu Simhadri
Venu Simhadri
NDNageshwar Reddy Duvvur
Nageshwar Reddy Duvvur
Despite effective vaccination programs, waning immunity in the vaccinated populations and the emergence of variants of concern posed a risk of breakthrough infections. A booster dose was demonstrated to provide substantially increased protection against symptomatic disease and hospitalization. We aimed to evaluate immune memory and the efficacy of reducing the rate of SARS-CoV-2 infection post heterologous booster with CORBEVAX after primary vaccination with two doses of COVISHIELD. SARS-CoV-2 S1/S2 spike IgG and RBD-specific antibody responses were elicited with both booster vaccines, with a greater response in individuals receiving heterologous booster. T and B memory responses were increased with booster dose, whereas B memory needed a longer duration to develop in individuals who received a homologous booster (90 days) in comparison to a heterologous booster (30 days). RBD-specific B memory and antibody-secreting (non-memory) B lymphocytes were enhanced with both boosters; however, the duration of response was longer with the heterologous booster compared to the homologous, indicating greater protection with the heterologous booster. The rate of infection 14 days after administration of the heterologous booster was comparatively lower than that of the homologous booster, with the symptoms being much less or asymptomatic.

26 August 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
RBRatnakar R. Bynigeri
Ratnakar R. Bynigeri
SMSasikala Mitnala
Sasikala Mitnala
RTRupjyoti Talukdar
Rupjyoti Talukdar
SSSurya S. Singh
Surya S. Singh
NDNageshwar R. Duvvuru
Nageshwar R. Duvvuru

19 July 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
VKVijayasarathy Ketavarapu
Vijayasarathy Ketavarapu
VRVishnubhotla Ravikanth
Vishnubhotla Ravikanth
SMSasikala Mitnala
Sasikala Mitnala
GRG. V. Rao
G. V. Rao
CDCh. Venkataramana Devi
Ch. Venkataramana Devi
DRD. Nageshwar Reddy
D. Nageshwar Reddy
Pathophysiology of transformation of inflammatory lesions in chronic pancreatitis (CP) to pancreatic ductal adenocarcinoma (PDAC) is not clear. We conducted a systematic review, meta-analysis of circulating metabolites, integrated this data with transcriptome analysis of human pancreatic tissues and validated using immunohistochemistry. Our aim was to establish biomarker signatures for early malignant transformation in patients with underlying CP and identify therapeutic targets. Analysis of 19 studies revealed AUC of 0.86 (95% CI 0.81-0.91, P < 0.0001) for all the altered metabolites (n = 88). Among them, lipids showed higher differentiating efficacy between PDAC and CP; P-value (< 0.0001). Pathway enrichment analysis identified sphingomyelin metabolism (impact value-0.29, FDR of 0.45) and TCA cycle (impact value-0.18, FDR of 0.06) to be prominent pathways in differentiating PDAC from CP. Mapping circulating metabolites to corresponding genes revealed 517 altered genes. Integration of these genes with transcriptome data of CP and PDAC with a background of CP (PDAC-CP) identified three upregulated genes; PIGC, PPIB, PKM and three downregulated genes; AZGP1, EGLN1, GNMT. Comparison of CP to PDAC-CP and PDAC-CP to PDAC identified upregulation of SPHK1, a known oncogene. Our analysis suggests plausible role for SPHK1 in development of pancreatic adenocarcinoma in long standing CP patients. SPHK1 could be further explored as diagnostic and potential therapeutic target.